Yingkerei

Yingkerei is a specialized biopharmaceutical company based in Shenzhen, China, focusing on the development of high-end inhalation drug delivery systems. The company addresses the significant technical challenges of respiratory medicine by integrating drug formulation with advanced device engineering, including Dry Powder Inhalers (DPI) and Metered-Dose Inhalers (MDI). Its pipeline features a range of treatments for asthma, chronic obstructive pulmonary disease (COPD), and pulmonary arterial hypertension, consisting of both high-quality generics and improved therapeutic candidates. By leveraging its proprietary inhalation technology platforms, Yingkerei aims to provide cost-effective alternatives to global blockbuster respiratory products for the Chinese and international markets.